Need a report that reflects how COVID-19 has impacted this market and its growth?
The biopharmaceuticals market was valued at approximately USD 325.17 billion in 2020, and it is expected to witness a revenue of USD 496.71 billion in 2026, with a CAGR of 7.32% over the forecast period, 2021-2026.
The ongoing COVID-19 pandemic globally is expected to have a significant impact on the biopharmaceutical industry. Most of the biopharmaceutical companies are striving extensively for the development of vaccines against the SARS-CoV2 virus. Some of the candidates are traditional-type vaccines such as inactivated and attenuated products; however, most of the vaccine candidates being developed are advanced DNA, RNA, and protein subunit vaccines. This factor is expected to boost the growth of the biopharmaceuticals market over the pandemic. However, the clinical and regulatory procedures for drug candidates of other indications may witness a slow pace due to the shifting priorities of the healthcare system to reduce the infections to clinical trial patients.
The market is largely driven by the growing geriatric population, rising chronic diseases, and increasing acceptance of and huge market demand for biopharmaceuticals. According to the Globocan 2020 report, a total of 19,292,789 new cancer cases were diagnosed, with 9,958,133 deaths due to cancers worldwide. Additionally, as per the data from the United Nations World Population Prospects 2019 report, by 2050, one in six people in the world will be over 65 years of age, which is an increase from one in 11 in 2019, and by 2050, one in four persons living in Europe and Northern America could be aged 65 years or over. The number of persons aged 80 years or over globally is projected to triple, from 143 million in 2019 to 426 million in 2050.
The huge demand for biopharmaceuticals is facilitated by an accelerating focus on research and related investments. The ability of biopharmaceutical products to address previously untreatable conditions has introduced innovative drugs in the market. Thus, given the aforementioned factors, the studied market is expected to grow over the forecast period.
Also, the market demand for biopharmaceuticals is increasing with the rising desire to circumvent the side effects associated with some small-molecule therapeutics and invasive surgical treatments. However, stringent regulatory issues and the requirement of high investment in the development of a biopharmaceutical drug are the growth limiting factors for the studied market.
Scope of the Report
As per the scope of the report, biopharmaceuticals refer to any biologically synthesized molecule used to treat or manage disorders. Biopharmaceutical products include (but are not limited to) monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, synthetic immunomodulators, cell and gene therapies, and other products. The biopharmaceuticals market is segmented by product type, therapeutic application, and geography. By product type, the market is segmented into monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, synthetic immunomodulators, and other product types. By therapeutic application, the market is segmented into oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, hormonal disorders, cardiovascular diseases, neurological diseases, and other diseases. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The report offers values (in USD million) for the above segments.
|By Product Type|
|By Therapeutic Application|
|Inflammatory and Infectious Diseases|
Key Market Trends
The Monoclonal Antibodies Segment is Expected to Hold a High Market Share During the Forecast Period
The successful use of monoclonal antibodies and antibody derivatives in therapeutics is the major driver for the rapid growth of the studied segment. The therapeutic applications of monoclonal antibodies include in the areas of cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases, among others.
The recent COVID-19 outbreak has been creating a huge burden on healthcare systems. Researchers across the world are continuously making efforts to cope with this rising burden. Thus, the demand for monoclonal antibodies targeting COVID-19 is likely to exceed. For instance, in July 2020, an anti-CD6 IgG1 monoclonal antibody named Itolizumab (ALZUMAb), from Biocon Ltd, India, was approved by the Drugs Controller General of India (DCGI) for the emergency treatment of cytokine release syndrome in acute respiratory distress syndrome patients infected with COVID-19.
Additionally, the growing FDA approvals and new product launches for various indications are expected to drive the segment. For instance, in October 2019, Novartis received the FDA approval for its Beovu (brolucizumab) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD). In March 2019, the US FDA approved Pfizer’s oncology biosimilar, TRAZIMERA, which is a monoclonal antibody biosimilar to the originator biologic medicine, Herceptin. Thus, owing to the aforementioned factors, the monoclonal antibodies segment is anticipated to witness significant growth over the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and is Expected to do the Same in the Forecast Period
The growing burden of chronic disease and increasing investments in research and development activities in the United States are the major factors driving the biopharmaceuticals market in North America. The United States has been recognized as the innovation capital of the world for life sciences, and it is involved in global capital investments in the early stages of biopharmaceutical companies.
During the present COVID-19 pandemic, almost all the biopharmaceutical companies in the region have been striving for the development of effective therapeutics against COVID-19, and this is expected to boost the studied market over the pandemic in North America. According to the Pharmaceutical Research and Manufacturers of America, as of January 2021, nearly 1,750 clinical trials were in progress for the development of vaccines and drugs in the treatment of COVID-19, among which 420 clinical trials were based in the United States.
According to Globocan 2020, the estimated incidence of cancer cases in the United States accounted for 2,281,658, with 612,390 deaths, in 2020. The high incidence of cancer surges the demand for effective therapeutics, and thus, drives the studied market. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), in 2018, more than 4.7 million people worked in the US biopharmaceutical industry across a broad spectrum of occupations, including scientific research, technical support, and manufacturing. Additionally, in March 2020, Thermo Fisher Scientific Inc. invested nearly USD 475 million as a biopharma investment in the expansion of biologics, cell and gene therapy, and drug product development and to increase its commercial capabilities globally. Similarly, in January 2020, Eli Lilly and Company entered an agreement to acquire Dermira, a biopharmaceutical company. This acquisition aids in the expansion of the company's biopharmaceutical portfolio with the addition of Dermira's lebrikizumab, an IL-13 antibody that is intended for use in the treatment of moderate-to-severe atopic dermatitis. Thus, given the aforementioned factors, the studied market is expected to propel significantly over the forecast period in North America.
To understand geography trends, Download Sample Report
The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by new product launches. Companies like Amgen Inc., Eli Lily and Company, Johnson and Johnson, Sanofi SA, AstraZeneca PLC, and Pfizer Inc. hold a significant share in the biopharmaceuticals market and are involved in various strategic alliances such as acquisitions and collaborations to expand their product portfolios. For instance, in August 2020, Sanofi SA entered a definitive agreement to acquire Principia Biopharma Inc., a late-stage biopharmaceutical company involved in the development of treatments for immune-mediated diseases.
In November 2020, the US Food and Drug Administration granted accelerated approval to naxitamab (DANYELZA) of Y-mAbs Therapeutics Inc. to be used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
In May 2020, Genmab AS received the US Food and Drug Administration approval for the use of the subcutaneous formulation of daratumumab, DARZALEX FASPRO, a monoclonal antibody (mAb) in the treatment of patients with multiple myeloma.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Acceptance and Huge Market Demand for Biopharmaceuticals
4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases
4.3 Market Restraints
4.3.1 High-end Manufacturing Requirements
4.3.2 Complicated and Cumbersome Regulatory Requirements
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size in Value)
5.1 By Product Type
5.1.1 Monoclonal Antibodies
188.8.131.52 Anti-cancer Monoclonal Antibodies
184.108.40.206 Anti-inflammatory Monoclonal Antibodies
220.127.116.11 Other Monoclonal Antibodies
5.1.2 Recombinant Growth Factors
18.104.22.168 Granulocyte Colony Stimulating Factor
5.1.3 Purified Proteins
22.214.171.124 Leukemia Inhibitory Factor (LIF)
126.96.36.199 P53 Protein
188.8.131.52 P38 Protein
184.108.40.206 Other Purified Proteins
5.1.4 Recombinant Proteins
220.127.116.11 Serum Albumin
18.104.22.168 Amyloid Protein
5.1.5 Recombinant Hormones
22.214.171.124 Recombinant Human Growth Hormones
126.96.36.199 Recombinant Insulin
188.8.131.52 Other Recombinant Hormones
184.108.40.206 Recombinant Vaccines
220.127.116.11.1 Cancer Vaccines
18.104.22.168.2 Malaria Vaccines
22.214.171.124.3 Ebola Vaccine
126.96.36.199.4 Hepatitis B Vaccine
188.8.131.52.5 Tetanus Vaccine
184.108.40.206.6 Diptheria Vaccine
220.127.116.11.7 Cholera Vaccine
18.104.22.168.8 Other Recombinant Vaccines
22.214.171.124 Conventional Vaccines
126.96.36.199.1 Polio Vaccine
188.8.131.52.2 Pox Vaccine
184.108.40.206.3 Other Conventional Vaccines
5.1.7 Recombinant Enzymes
5.1.8 Cell and Gene Therapies
220.127.116.11 Allogenic Products
18.104.22.168 Autologous Products
22.214.171.124 Acellular Products
5.1.9 Synthetic Immunomodulators
126.96.36.199 Cytokines, Interferons, and Interleukins
5.1.10 Other Product Types
188.8.131.52 Blood Factors
184.108.40.206 Other Product Types
5.2 By Therapeutic Application
5.2.2 Inflammatory and Infectious Diseases
5.2.3 Autoimmune Disorders
5.2.4 Metabolic Disorders
5.2.5 Hormonal Disorders
5.2.6 Cardiovascular Diseases
5.2.7 Neurological Diseases
5.2.8 Other Diseases
5.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East and Africa
5.3.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Amgen Inc.
6.1.3 Bristol-Myers Squibb Company
6.1.4 Eli Lilly and Company
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Novo Nordisk AS
6.1.8 Pfizer Inc.
6.1.9 GlaxoSmithKline PLC
6.1.10 F. Hoffmann-La Roche AG
6.1.11 Biogen Inc.
6.1.12 Merck Co. & Inc.
6.1.13 Sanofi SA
6.1.14 AstraZeneca PLC
6.1.15 Bayer AG
6.1.16 Takeda Pharmaceutical Company Limited
6.1.17 Agilent Technologies Inc.
6.1.18 Thermo Fisher Scientific Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Biopharmaceuticals Market market is studied from 2018 - 2026.
What is the growth rate of Global Biopharmaceuticals Market?
The Global Biopharmaceuticals Market is growing at a CAGR of 7.32% over the next 5 years.
Which region has highest growth rate in Global Biopharmaceuticals Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Biopharmaceuticals Market?
North America holds highest share in 2020.
Who are the key players in Global Biopharmaceuticals Market?
- Amgen Inc.
- Abbvie Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Novo Nordisk
Are the major companies operating in Global Biopharmaceuticals Market.